Immune Neonatal Thrombocytopenia (NAIT)

Definition And Epidemiology

Analogous to Rh incompatibility (Hemolytic Disease of the Fetus and Newborn).
Sensitization occurs early in pregnancy; explains high incidence in firstborns.
Fetal platelets express paternally inherited specific surface antigens.
Maternal immune system lacks these antigens; generates targeted alloantibodies.
Maternal IgG antibodies cross placenta, binding fetal platelets.
Antibody-coated fetal platelets destroyed by fetal reticuloendothelial system (macrophages).
Pathogenic antibodies likely inhibit endogenous fetal platelet production simultaneously.
Major antigens involved:
- HPA-1a: Implicated in 75-80% of cases.
- HPA-5b: Implicated in 10-20% of cases.
- HPA-4: Clinically significant in Asian populations (lack HPA-1a/b polymorphism).
Maternal genetic predisposition: HLA-DRB30101 expression increases alloimmunization risk to HPA-1a by 25-fold.

Pathology Overview: Antibody-mediated destruction of circulating fetal platelets and megakaryocyte suppression leads to profound bleeding diathesis. Unlike adult immune thrombocytopenia, the developing fetal brain vasculature is highly vulnerable to spontaneous rupture under severe thrombocytopenic conditions, leading to devastating intraparenchymal hemorrhages prior to the mechanical stress of delivery.
Presents in otherwise healthy, full-term neonates.
Profound thrombocytopenia typically evident at birth (platelet count <50,000/µL).
Widespread mucocutaneous bleeding: Generalized petechiae, ecchymosis.
Localized bleeding: Cephalohematoma, continuous oozing from venipuncture sites, umbilical stump bleeding.
Internal hemorrhage: Gastrointestinal or renal tract bleeding.
Intracranial Hemorrhage (ICH):
- Occurs in 10-20% of affected neonates.
- Pathology: Severe, destructive intraparenchymal bleeding.
- Timing: Frequently occurs in utero, rather than during delivery.
- Can be detected via prenatal ultrasonography during uncomplicated pregnancies.
- Can result in in utero fetal demise.

Suspect in all neonates presenting with unexplained severe thrombocytopenia.
Screen neonates with platelet counts <50,000/µL, even lacking bleeding symptoms.
Suspect if family history reveals transient neonatal thrombocytopenia in siblings.
Maternal platelet count remains normal; no history of maternal autoimmune thrombocytopenia.
Confirm diagnosis via specialized serological testing:
- Human Platelet Antigen (HPA) typing of mother and father.
- Screen maternal serum for platelet-specific alloantibodies (anti-HPA-1, 3, 5; add HPA-4 for Asian descent).
- Positive diagnosis requires demonstration of parental antigen incompatibility plus detection of discordant maternal antibody.
Lack of response to random donor platelet transfusion offers poor diagnostic utility.

Feature	Neonatal Alloimmune Thrombocytopenia	Neonatal Autoimmune Thrombocytopenia (Maternal ITP)
Pathogenesis	Maternal IgG targets fetal-specific (paternal) antigen	Maternal IgG targets shared antigen (e.g., GPIIb/IIIa)
Antigen Target	HPA-1a, HPA-5b	GPIIb/IIIa, GPIb/IX complex
Maternal Platelet Count	Normal	Low (unless post-splenectomy)
Maternal History	Normal (may have unrelated gestational thrombocytopenia)	Known ITP, Systemic Lupus Erythematosus (SLE), Hypothyroidism
Neonatal Platelet Count	Often <20,000/µL at birth	Often >50,000/µL at birth; drops over 1-3 days
Risk of ICH	High (10-20%); frequent in utero	Very low (<1-2%)
Primary Treatment	Random or matched donor platelets, IVIG	IVIG, Methylprednisolone
Resolution Time	2-4 weeks	3-12 weeks

Other Differentials:
- TORCH infections (Cytomegalovirus, Toxoplasmosis, Rubella); associated with microcephaly, hepatosplenomegaly, "blueberry muffin" rash.
- Disseminated Intravascular Coagulation (DIC) secondary to sepsis, asphyxia, or respiratory distress.
- Congenital bone marrow failure syndromes (e.g., Congenital Amegakaryocytic Thrombocytopenia, Thrombocytopenia-Absent Radius syndrome).

Transfuse platelets immediately for counts <30,000/µL or active bleeding.
Dose: 10-20 mL/kg body weight.
Random donor platelets frequently efficacious; utilize promptly.
Utilize matched donor or concentrated washed maternal platelets if random donor platelets fail.
Administer Intravenous Immunoglobulin (IVIG): 1 g/kg/day for 1-3 days.
Maintain platelet count >30,000/µL for stable patients; >50,000-100,000/µL for life-threatening hemorrhage.
Corticosteroids: Methylprednisolone 1 mg IV every 8 hours on days of IVIG administration.
Monitor platelet counts closely until resolution (usually 2-4 weeks) to prevent missing inherited thrombocytopenias.

Mandatory urgent cranial ultrasound for all severely thrombocytopenic neonates.
Perform Brain MRI (using feed and swaddle technique to avoid anesthesia) if ultrasound equivocal or abnormal neurological signs exist.
Documented ICH alters treatment target: Maintain platelets >100,000/µL.
Repeat imaging monthly for 3 months; monitor head circumference for early hydrocephalus.

Risk of recurrence high; management requires maternal-fetal medicine specialists.
Determine paternal zygosity: 75% of HPA-1a positive men are homozygous; confers 100% risk to subsequent fetuses.
Utilize noninvasive prenatal testing via cell-free fetal DNA (cffDNA) to determine fetal HPA status.
Avoid invasive percutaneous umbilical blood sampling due to severe complication risks.
Antenatal therapy stratification:
- Prior pregnancy with ICH: Initiate maternal IVIG at 12 weeks gestation.
- Prior pregnancy without ICH: Initiate maternal IVIG at 20 weeks gestation.
- Refractory cases: Increase IVIG dose or add maternal corticosteroids.
Delivery via cesarean section recommended to minimize mechanical trauma and prevent intrapartum ICH.

Excellent if hemorrhage avoided. Self-limiting disease.
Major morbidity and mortality linked strictly to in utero or perinatal intracranial hemorrhage. Early detection in subsequent pregnancies prevents neurological devastation.